Breaking

Russian International Reserves Fall $15.7 Billion in Week to Dec. 19
Tweet TWEET

Pacific Biosciences Appoints John F. Milligan to Board of Directors

Pacific Biosciences Appoints John F. Milligan to Board of Directors

Gilead Sciences Executive Recognized for Financial Leadership in Biotech
Industry

MENLO PARK, Calif., July 18, 2013 (GLOBE NEWSWIRE) -- Pacific Biosciences of
California, Inc. (Nasdaq:PACB), provider of the PacBio^® RS II DNA Sequencing
System, today announced that John F. Milligan, Ph.D. has joined the Company's
Board of Directors. Dr. Milligan currently serves as President and Chief
Operating Officer of Gilead Sciences.

Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was
made Director of Project Management and Project Team Leader for the Gilead
Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was
appointed Chief Financial Officer. He was named Chief Operating Officer in
2007 and President in 2008.

Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with
revenues greater than $500 million, and he was named the top biotechnology
industry CFO in the United States by Institutional Investor magazine in 2006,
2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology
Industry Organization (BIO), the largest biotechnology industry organization.
Dr. Milligan is a Trustee of Ohio Wesleyan University. He received his BA from
Ohio Wesleyan University, his Ph.D. in biochemistry from the University of
Illinois and was an American Cancer Society postdoctoral fellow at the
University of California at San Francisco.

"John is a prominent and well-respected figure in the biotechnology industry,
and we are delighted to have him join our Board of Directors," said Michael
Hunkapiller, CEO and Chairman of the Board of Directors of Pacific
Biosciences. "The combination of scientific and business expertise he brings
will be a valuable addition to PacBio."

Dr. Milligan commented: "I'm very pleased to join the Board of Pacific
Biosciences, and I look forward to working with my fellow directors and the
senior management team to further the company's mission of delivering tools
and technology that are helping to drive scientific and medical innovation."

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio^® RS
II DNA Sequencing System to help scientists solve genetically complex
problems. Based on its novel Single Molecule, Real-Time (SMRT^®) technology,
the company's products enable: targeted sequencing to more comprehensively
characterize genetic variations; de novo genome assembly to more fully
identify, annotate and decipher genomic structures; and DNA base modification
identification to help characterize epigenetic regulation and DNA damage. By
providing access to information that was previously inaccessible, Pacific
Biosciences enables scientists to increase their understanding of biological
systems. More information is available at www.pacb.com.

CONTACT: Media:
         Nicole Litchfield
         For Pacific Biosciences
         415.793.6468
         nicole@bioscribe.com
        
         Investors:
         Trevin Rard
         Pacific Biosciences
         650.521.8450
         ir@pacificbiosciences.com
 
Press spacebar to pause and continue. Press esc to stop.